Trial Profile
Post-eRADicAte: A Long Term Follow up to eRADicAte (NCT 02097303), an Open Label Phase Two Study of RADium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in CRPC Subjects With Symptomatic Bone Metastasis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Abiraterone acetate; Prednisone
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms Post-eRADicAte
- 08 Oct 2021 According to ClinicalTrials.gov: US National Institutes of Health status of the trial is unknown as the information has not been verified recently(Last verified:Mar 2019 ).
- 15 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 New trial record